These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 30417950)

  • 1. Does global drug innovation correspond to burden of disease? The neglected diseases in developed and developing countries.
    Barrenho E; Miraldo M; Smith PC
    Health Econ; 2019 Jan; 28(1):123-143. PubMed ID: 30417950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health innovation networks to help developing countries address neglected diseases.
    Morel CM; Acharya T; Broun D; Dangi A; Elias C; Ganguly NK; Gardner CA; Gupta RK; Haycock J; Heher AD; Hotez PJ; Kettler HE; Keusch GT; Krattiger AF; Kreutz FT; Lall S; Lee K; Mahoney R; Martinez-Palomo A; Mashelkar RA; Matlin SA; Mzimba M; Oehler J; Ridley RG; Senanayake P; Singer P; Yun M
    Science; 2005 Jul; 309(5733):401-4. PubMed ID: 16020723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease burden metrics and the innovations of leading pharmaceutical companies: a global and regional comparative study.
    Jung YL; Hwang J; Yoo HS
    Global Health; 2020 Sep; 16(1):80. PubMed ID: 32912258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innovation and the burden of disease: retrospective observational study of new and emerging health technologies reported by the EuroScan Network from 2000 to 2009.
    Martino OI; Ward DJ; Packer C; Simpson S; Stevens A
    Value Health; 2012; 15(2):376-80. PubMed ID: 22433770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceutical innovation and the burden of disease in developing and developed countries.
    Lichtenberg FR
    J Med Philos; 2005 Dec; 30(6):663-90. PubMed ID: 16396790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring why global health needs are unmet by research efforts: the potential influences of geography, industry and publication incentives.
    Yegros-Yegros A; van de Klippe W; Abad-Garcia MF; Rafols I
    Health Res Policy Syst; 2020 May; 18(1):47. PubMed ID: 32414373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing the latest framework to measure and incentivise pharmaceutical industry contributions to health research and development.
    Cole CB; Trolle S; Edwards DJ
    Health Res Policy Syst; 2018 Aug; 16(1):73. PubMed ID: 30071858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New strategies for innovation in global health: a pharmaceutical industry perspective.
    Witty A
    Health Aff (Millwood); 2011 Jan; 30(1):118-26. PubMed ID: 21209447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First Universities Allied for Essential Medicines (UAEM) Neglected Diseases and Innovation Symposium.
    Musselwhite LW; Maciag K; Lankowski A; Gretes MC; Wellems TE; Tavera G; Goulding RE; Guillen E
    Am J Trop Med Hyg; 2012 Jan; 86(1):65-74. PubMed ID: 22232453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poverty-related and neglected diseases - an economic and epidemiological analysis of poverty relatedness and neglect in research and development.
    von Philipsborn P; Steinbeis F; Bender ME; Regmi S; Tinnemann P
    Glob Health Action; 2015; 8():25818. PubMed ID: 25623607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global burden of disease: huge inequities in the health status in developing and developed countries.
    Sentes K; Kipp W
    Healthc Manage Forum; 2003; 16(3):27-9. PubMed ID: 14618830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dengue Vaccines: A Perspective from the Point of View of Intellectual Property.
    da Veiga CP; da Veiga CR; Del Corso JM; da Silva WV
    Int J Environ Res Public Health; 2015 Aug; 12(8):9454-74. PubMed ID: 26274968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Privatized Pharmaceutical Innovation vs Access to Essential Medicines: A Global Framework for Equitable Sharing of Benefits.
    Burci GL; Gostin LO
    JAMA; 2017 Feb; 317(5):473-474. PubMed ID: 28170485
    [No Abstract]   [Full Text] [Related]  

  • 14. Revisiting the concept of Innovative Developing Countries (IDCs) for its relevance to health innovation and neglected tropical diseases and for the prevention and control of epidemics.
    Vasconcellos AG; Fonseca E Fonseca BP; Morel CM
    PLoS Negl Trop Dis; 2018 Jul; 12(7):e0006469. PubMed ID: 30001318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing 15 proposals for promoting innovation and access to medicines globally.
    Hoffman SJ; So K;
    Ann Glob Health; 2014; 80(6):432-43. PubMed ID: 25960092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regional patterns of disability-free life expectancy and disability-adjusted life expectancy: global Burden of Disease Study.
    Murray CJ; Lopez AD
    Lancet; 1997 May; 349(9062):1347-52. PubMed ID: 9149696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Status of research and development for control of tropical diseases: hypocrisy, indifference or lack of coordination].
    Millet P
    Med Trop (Mars); 2006 Dec; 66(6):542-8. PubMed ID: 17286017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global pharmacogenomics: where is the research taking us?
    Olivier C; Williams-Jones B
    Glob Public Health; 2014; 9(3):312-24. PubMed ID: 24580118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining innovation.
    Hughes B
    Nat Rev Drug Discov; 2009 Sep; 8(9):683-4. PubMed ID: 19721435
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.